{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:50:17Z","timestamp":1791226217345,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.clgc.2015.09.005","type":"journal-article","created":{"date-parts":[[2015,9,25]],"date-time":"2015-09-25T17:37:20Z","timestamp":1443202640000},"page":"176-182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["EORTC Risk Model to Predict Progression in Patients With Non\u2013Muscle-Invasive Bladder Cancer: Is It Safe to Use in Clinical Practice?"],"prefix":"10.1016","volume":"14","author":[{"given":"Wilson F.S.","family":"Busato J\u00fanior","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto Laurino","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen A.P.M.","family":"Ribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurandir M.","family":"Ribas Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ottavio","family":"De Cobelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2015.09.005_bib1","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","article-title":"EAU Guidelines on non\u2013muscle-invasive urothelial carcinoma of the bladder: update, 2013","volume":"64","author":"Babjuk","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2015.09.005_bib2","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eursup.2008.08.002","article-title":"Epidemiology, staging, grading, and risk stratification of bladder cancer","volume":"7","author":"Colombel","year":"2008","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.clgc.2015.09.005_bib3","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.eursup.2009.06.010","article-title":"Recurrence, progression, and follow-up in non\u2013muscle-invasive bladder cancer","volume":"8","author":"Van der Heijden","year":"2009","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.clgc.2015.09.005_bib4","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2015.09.005_bib5","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.eururo.2015.01.032","article-title":"Prognostic and prediction tools in bladder cancer: a comprehensive review of the literature","volume":"68","author":"Kluth","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2015.09.005_bib6","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","article-title":"Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors","volume":"15","author":"Harrell","year":"1996","journal-title":"Stat Med"},{"key":"10.1016\/j.clgc.2015.09.005_bib7","first-page":"1071","article-title":"Regression models for prognostic prediction: advantages, problems, and suggested solutions","volume":"69","author":"Harrell","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.clgc.2015.09.005_bib8","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4111\/kju.2010.51.3.165","article-title":"The efficacy of the EORTC scoring system and risk tables for the prediction of recurrence and progression of non\u2013muscle-invasive bladder cancer after intravesical bacillus Calmette-Gu\u00e9rin instillation","volume":"51","author":"Seo","year":"2010","journal-title":"Korean J Urol"},{"key":"10.1016\/j.clgc.2015.09.005_bib9","first-page":"189","article-title":"Predicting recurrence and progression in non\u2013muscle invasive bladder cancer using European Organization of Research and Treatment of Cancer risk tables","volume":"6","author":"Ather","year":"2009","journal-title":"Urol J"},{"key":"10.1016\/j.clgc.2015.09.005_bib10","first-page":"1518","article-title":"Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder","volume":"173","author":"Shariat","year":"2005","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2015.09.005_bib11","doi-asserted-by":"crossref","first-page":"e96849","DOI":"10.1371\/journal.pone.0096849","article-title":"Risk prediction scores for recurrence and progression of non\u2013muscle invasive bladder cancer: an international validation in primary tumours","volume":"9","author":"Vedder","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clgc.2015.09.005_bib12","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.eururo.2011.06.001","article-title":"How well can you actually predict which non\u2013muscle-invasive bladder cancer patients will progress?","volume":"60","author":"Sylvester","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2015.09.005_bib13","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.eururo.2011.05.033","article-title":"The EORTC tables overestimate the risk of recurrence and progression in patients with non\u2013muscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin: external validation of the EORTC risk tables","volume":"60","author":"Fernandez-Gomez","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2015.09.005_bib14","doi-asserted-by":"crossref","first-page":"b605","DOI":"10.1136\/bmj.b605","article-title":"Prognosis and prognostic research: validating a prognostic model","volume":"338","author":"Altman","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.clgc.2015.09.005_bib15","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1055\/s-0038-1636443","article-title":"The measurement of performance in probabilistic diagnosis. III. Methods based on continuous functions of the diagnostic probabilities","volume":"17","author":"Hilden","year":"1978","journal-title":"Methods Inf Med"},{"key":"10.1016\/j.clgc.2015.09.005_bib16","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00345-010-0635-2","article-title":"External validation and applicability of the EORTC risk tables for non\u2013muscle-invasive bladder cancer","volume":"29","author":"Hern\u00e1ndez","year":"2011","journal-title":"World J Urol"},{"key":"10.1016\/j.clgc.2015.09.005_bib17","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.eururo.2010.05.043","article-title":"Molecular grade (FGFR3\/MIB-1) and EORTC risk score are predictive in primary non\u2013muscle-invasive bladder cancer","volume":"58","author":"Van Rhijn","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2015.09.005_bib18","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/bju.12495","article-title":"Comparison of expected treatment outcome provided by risk models and international guidelines with observed treatment outcome in a cohort of Dutch non\u2013muscle-invasive bladder cancer patients treated with intravesical chemotherapy","volume":"114","author":"Lammers","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2015.09.005_bib19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.canep.2014.02.001","article-title":"Are EORTC risk tables suitable for Chinese patients with nonmuscle-invasive bladder cancer?","volume":"38","author":"Ding","year":"2014","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.clgc.2015.09.005_bib20","first-page":"609","article-title":"Efficacy of European Organization for Research and Treatment of Cancer (EORTC) risk tables for the prediction of recurrence and progression of non\u00acmuscle invasive bladder cancer after intravesical pirarubicin instillation","volume":"34","author":"Xu","year":"2012","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"10.1016\/j.clgc.2015.09.005_bib21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000336516","article-title":"Recurrence and progression in non\u2013muscle-invasive bladder cancer using EORTC risk tables","volume":"89","author":"Altieri","year":"2012","journal-title":"Urol Int"},{"key":"10.1016\/j.clgc.2015.09.005_bib22","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3109\/01913123.2013.786772","article-title":"The efficiency of the EORTC scoring system for the prediction of recurrence and progression of non\u2013muscle-invasive bladder cancer treated by bacillus Calmette-Gu\u00e9rin immunotherapy","volume":"37","author":"Ajili","year":"2013","journal-title":"Ultrastruct Pathol"},{"key":"10.1016\/j.clgc.2015.09.005_bib23","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1100\/tsw.2011.77","article-title":"Do standardised prognostic algorithms reflect local practice? Application of EORTC risk tables for non\u2013muscle invasive (pTa\/pT1) bladder cancer recurrence and progression in a local cohort","volume":"11","author":"Pillai","year":"2011","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.clgc.2015.09.005_bib24","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1038\/bjc.2013.372","article-title":"Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non\u2013muscle-invasive urothelial carcinoma of the bladder","volume":"109","author":"Xylinas","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2015.09.005_bib25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5173\/ceju.2013.01.art5","article-title":"EORTC risk tables\u2014their usefulness in the assessment of recurrence and progression risk in non\u2013muscle-invasive bladder cancer in Polish patients","volume":"66","author":"Borkowska","year":"2013","journal-title":"Cent Eur J Urol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767315002463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767315002463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:26:12Z","timestamp":1761564372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767315002463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S1558767315002463"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2015.09.005","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EORTC Risk Model to Predict Progression in Patients With Non\u2013Muscle-Invasive Bladder Cancer: Is It Safe to Use in Clinical Practice?","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2015.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}